← Eichor
Study identifier: NCT07434713 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

EarLy Treatment Response in nEoVascular Macular Degeneration With Eylea 8mg: ELEV8 A Prospective Observational Open Label Study Investigating the Fluid Dynamics During Early Response to Aflibercept 8mg in Patients With Exudative Age-related Macular Degeneration (AMD).

Condition: Age-Related Macular Degeneration (AMD)  ·  Sponsor: Insel Gruppe AG, University Hospital Bern

PhaseN/A
Planned participants50
Who can joinAll sexes, 50 Years to no upper limit
Healthy volunteersNo

About this study

This prospective, observational, open-label study evaluates early treatment response to intravitreal aflibercept 8 mg in patients with exudative age-related macular degeneration. Retinal fluid dynamics assessed by optical coherence tomography and changes in best-corrected visual acuity two months after baseline are analyzed to characterize early treatment outcomes.

This description comes directly from the study's public registry record.

Talk to the study team

Florian M Heussen, Dr. med.  ·  +41 (0)31 664 54 24  ·  florian.heussen@insel.ch

Martin S Zinkernagel, Prof. Dr. Dr. med.  ·  +41 (0)31 632 85 03  ·  martin.zinkernagel@insel.ch

Always discuss trial participation with your own doctor first.

Locations (1)

Dept. of Ophthalmology, University Hospital, InselspitalBern, SwitzerlandRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07434713